Table 3 TGF-β1 levels and baseline characteristics according to two groups determined by a TGF-β1 trajectory analysis
n | Group 1 | n | Group 2 | p | |
|---|---|---|---|---|---|
TGF-β1 before RT (ng/ml) Md (IQR) | 19 | 25.6 (22.3–28.6) | 44 | 17.8 (15.9–19.9) | < 0.001 |
TGF-β1 after RT (ng/ml), Md (IQR) | 19 | 23.9 (21.3–25.2) | 44 | 16.3 (13.7–19.1) | < 0.001 |
TGF-β1 at 3 years (ng/ml), Md (IQR) | 19 | 22.4 (18.8–25.8) | 44 | 15.0 (12.1–18.8) | < 0.001 |
Age, Md (IQR) | 19 | 64 (58–66) | 44 | 64 (59–68) | 0.752 |
BMI, Md (IQR) | 19 | 26.9 (24.8–32.3) | 44 | 25.7 (24.1–28.7) | 0.110 |
Left-sided BC, n (%) | 19 | 14 (73.7) | 44 | 36 (81.8) | 0.508 |
AI-use, n (%) | 19 | 6 (31.2) | 44 | 15 (34.1) | 1.000 |
Tamoxifen use, n (%) | 19 | 2 (10.5) | 44 | 4 (9.1) | 1.000 |
ACE or ARB use, n (%) | 19 | 5 (26.3) | 44 | 12 (27.3) | 1.000 |
ASA use, n (%) | 19 | 1 (5.3) | 44 | 4 (9.1) | 1.000 |
Beta-blocker use, n (%) | 19 | 4 (21.1) | 44 | 7 (15.9) | 0.721 |
Statin use, n (%) | 19 | 3 (15.8) | 44 | 10 (22.7) | 0.738 |
CAD, n (%) | 19 | 2 (10.5) | 44 | 1 (2.3) | 0.214 |
Diabetes, n (%) | 17 | 3 (17.6) | 42 | 2 (4.8) | 0.138 |
Hypertension, n (%) | 19 | 9 (47.4) | 44 | 15 (34.1) | 0.400 |
Hypothyroidism, n (%) | 19 | 3 (15.8) | 44 | 7 (15.9) | 1.000 |
Smoking, n (%) | 19 | 2 (10.5) | 44 | 5 (11.4) | 1.000 |